R&D Towards better quality of life, GNT Pharma

Clinical Research

RODINRescues On reperfusion Damage in cerebral Infarction by Nelonemdaz

  • Phase III clinical study in Korea to verify the improvement and neuroprotective effect of nelonemdaz in 496 patients with acute ischemic stroke undergoing surgery to remove a blood clot within 12 hours following last known normal.
  • Participating Hospitals (Department of Neurology): 24 University hospitals including Asan Medical Center in Seoul
  • IND Approval Date: August 2021 (first patient enrolled on December 25, 2021)
Total No. of
Enrolled Patients
Progress RateAs of June 7, 2022
107 Pts. 21.6%
Target No. of Patients 496 Pts.